1
Clinical Trials associated with CALRLong36 peptide(Herlev Hospital)A Phase-1-first in Man Study in Patients With CALR-mutant Myeloproliferative Neoplasms by Vaccinating With CALR Exon 9 Mutant Peptide
A phase-I-first in man study in patients with calreticulin(CALR)-mutant MPN by vaccinating with exon 9 mutated peptide with the adjuvant Montanide ISA-51 to monitor safety and toxicity and the immunological response to vaccination.
100 Clinical Results associated with CALRLong36 peptide(Herlev Hospital)
100 Translational Medicine associated with CALRLong36 peptide(Herlev Hospital)
100 Patents (Medical) associated with CALRLong36 peptide(Herlev Hospital)
100 Deals associated with CALRLong36 peptide(Herlev Hospital)